Breaking News

Over a week ago
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Hot Stocks
Candel Therapeutics announces key upcoming milestones » 08:23
09/08/21
09/08
08:23
09/08/21
08:23
CADL

Candel Therapeutics

$9.87 /

+1.77 (+21.85%)

Initial efficacy and…

Initial efficacy and safety data from a phase 1 clinical trial of CAN-2409 in combination with Opdivo in patients with high-grade glioma are expected to be presented in the fourth quarter of 2021. Blinded safety data from a phase 2 clinical trial of CAN-2409 in patients undergoing active surveillance for prostate cancer are expected to be presented in the third quarter of 2021. Biomarker results from a phase 1 clinical trial of CAN-3110 in patients with recurrent high-grade glioma are expected to be presented in the fourth quarter of 2021.

ShowHide Related Items >><<
CADL Candel Therapeutics
$9.87 /

+1.77 (+21.85%)

CADL Candel Therapeutics
$9.87 /

+1.77 (+21.85%)

08/23/21 UBS
Candel Therapeutics initiated with a Buy at UBS
08/23/21 Jefferies
Candel Therapeutics initiated with a Buy at Jefferies
08/23/21 Credit Suisse
Candel Therapeutics initiated with an Outperform at Credit Suisse
CADL Candel Therapeutics
$9.87 /

+1.77 (+21.85%)

  • 27
    Jul
CADL Candel Therapeutics
$9.87 /

+1.77 (+21.85%)

Hot Stocks
Candel Therapeutics expects cash to fund operations into 2Q23 » 08:22
09/08/21
09/08
08:22
09/08/21
08:22
CADL

Candel Therapeutics

$9.87 /

+1.77 (+21.85%)

Cash and cash equivalents…

Cash and cash equivalents as of June 30, 2021, were $24.3 million, as compared to $35.1 million as of December 31, 2020. In August 2021, Candel completed its initial public offering in which the Company issued 9,887,994 shares of common stock at a price of $8.00 per share, including the partial exercise of the underwriters' overallotment option, for net proceeds of $71.5 million after deducting underwriting discounts and commissions and offering expenses. Based on current plans and assumptions, the Company expects its existing cash and cash equivalents, including the net proceeds of the IPO, will be sufficient to fund its operations into the second quarter of 2023.

ShowHide Related Items >><<
CADL Candel Therapeutics
$9.87 /

+1.77 (+21.85%)

CADL Candel Therapeutics
$9.87 /

+1.77 (+21.85%)

08/23/21 UBS
Candel Therapeutics initiated with a Buy at UBS
08/23/21 Jefferies
Candel Therapeutics initiated with a Buy at Jefferies
08/23/21 Credit Suisse
Candel Therapeutics initiated with an Outperform at Credit Suisse
CADL Candel Therapeutics
$9.87 /

+1.77 (+21.85%)

  • 27
    Jul
CADL Candel Therapeutics
$9.87 /

+1.77 (+21.85%)

Earnings
Candel Therapeutics reports Q2 EPS ($1.46), one est. (12c) » 08:21
09/08/21
09/08
08:21
09/08/21
08:21
CADL

Candel Therapeutics

$9.87 /

+1.77 (+21.85%)

"This has been a…

"This has been a transformational year for Candel Therapeutics as we continue to execute on our corporate strategy by advancing the development of our lead product candidate from our adenovirus platform, CAN-2409, and our lead product candidate from our HSV platform, CAN-3110, both in areas of significant unmet need," said Paul Peter Tak, M.D., Ph.D., FMedSci, President and Chief Executive Officer of Candel Therapeutics. "With the completion of our IPO in August and multiple data readouts across our broad pipeline over the next 12 months, we are in a strong position to advance our strategy and well-capitalized to support achievement of important milestones toward bringing novel immunotherapies to patients with cancer."

ShowHide Related Items >><<
CADL Candel Therapeutics
$9.87 /

+1.77 (+21.85%)

CADL Candel Therapeutics
$9.87 /

+1.77 (+21.85%)

08/23/21 UBS
Candel Therapeutics initiated with a Buy at UBS
08/23/21 Jefferies
Candel Therapeutics initiated with a Buy at Jefferies
08/23/21 Credit Suisse
Candel Therapeutics initiated with an Outperform at Credit Suisse
  • 27
    Jul
CADL Candel Therapeutics
$9.87 /

+1.77 (+21.85%)

Hot Stocks
Candel Therapeutics completes enrollment in Phase 2 trial of CAN-2409 » 08:11
09/07/21
09/07
08:11
09/07/21
08:11
CADL

Candel Therapeutics

$8.17 /

+0.075 (+0.93%)

Candel Therapeutics…

Candel Therapeutics announced that it has completed patient enrollment for its pivotal phase 3 study of CAN-2409 immunotherapy in patients with intermediate-high risk localized prostate cancer. This placebo-controlled, randomized clinical trial is evaluating CAN-2409 treatment in combination with valacyclovir added to upfront standard of care external beam radiation therapy for patients with localized prostate cancer compared to standard of care radiation therapy alone. The primary endpoint of the study is disease-free survival. Secondary endpoints include prostate cancer specific survival, overall survival, freedom from biochemical failure, patient reported health-related quality of life, and safety.

ShowHide Related Items >><<
CADL Candel Therapeutics
$8.17 /

+0.075 (+0.93%)

CADL Candel Therapeutics
$8.17 /

+0.075 (+0.93%)

08/23/21 UBS
Candel Therapeutics initiated with a Buy at UBS
08/23/21 Jefferies
Candel Therapeutics initiated with a Buy at Jefferies
08/23/21 Credit Suisse
Candel Therapeutics initiated with an Outperform at Credit Suisse
  • 27
    Jul
CADL Candel Therapeutics
$8.17 /

+0.075 (+0.93%)

Initiation
Candel Therapeutics initiated with a Buy at UBS » 09:07
08/23/21
08/23
09:07
08/23/21
09:07
CADL

Candel Therapeutics

$6.20 /

+0.49 (+8.58%)

UBS analyst Colin Bristow…

UBS analyst Colin Bristow initiated coverage of Candel Therapeutics with a Buy rating and $9 price target. The analyst states that the company's early data from the lead asset CAN-2409 has shown promise in prostate cancer and brain tumors, with registration-enabling trials near-fully enrolled for the former and expected to enroll in the first half of next year for the latter. Bristow adds that the data for CAN-2409 and CAN-3110 is challenging to interpret due to a variety of factors, but both assets have shown clear signs of activity, and he believes that the current trading range under-appreciates their risk-adjusted shots on goal.

ShowHide Related Items >><<
CADL Candel Therapeutics
$6.20 /

+0.49 (+8.58%)

CADL Candel Therapeutics
$6.20 /

+0.49 (+8.58%)

08/23/21 Jefferies
Candel Therapeutics initiated with a Buy at Jefferies
08/23/21 Credit Suisse
Candel Therapeutics initiated with an Outperform at Credit Suisse
  • 27
    Jul
CADL Candel Therapeutics
$6.20 /

+0.49 (+8.58%)

Initiation
Candel Therapeutics initiated with a Buy at Jefferies » 07:32
08/23/21
08/23
07:32
08/23/21
07:32
CADL

Candel Therapeutics

$6.20 /

+0.49 (+8.58%)

Jefferies analyst Chris…

Jefferies analyst Chris Howerton initiated coverage of Candel Therapeutics with a Buy rating and $22 price target. Howerton views Phase 3 prostate data for CAN-2409 in 2024, with multiple incremental Phase 1/2 readouts in 2022 and 2023 as key catalysts, and likes Candel given the pipeline opportunities in both prostate and brain cancers, as well as continued growth through the platform, the analyst tells investors in a research note.

ShowHide Related Items >><<
CADL Candel Therapeutics
$6.20 /

+0.49 (+8.58%)

CADL Candel Therapeutics
$6.20 /

+0.49 (+8.58%)

08/23/21 Credit Suisse
Candel Therapeutics initiated with an Outperform at Credit Suisse
  • 27
    Jul
CADL Candel Therapeutics
$6.20 /

+0.49 (+8.58%)

Initiation
Candel Therapeutics initiated with an Outperform at Credit Suisse » 06:31
08/23/21
08/23
06:31
08/23/21
06:31
CADL

Candel Therapeutics

$6.20 /

+0.49 (+8.58%)

Credit Suisse analyst…

Credit Suisse analyst Judah Frommer initiated coverage of Candel Therapeutics with an Outperform rating and $15 price target. Candel offers investors an immunotherapy platform with multiple ongoing late-stage clinical programs, Frommer tells investors in a research note. The analyst says the company's two oncolytic virus-based approaches allow for local tumor targeting to reduce the risk of systemic toxicities, are amenable to genetic engineering for enhanced specificity, and have the potential as an adjunct therapy to complement the existing standard of care.

ShowHide Related Items >><<
CADL Candel Therapeutics
$6.20 /

+0.49 (+8.58%)

  • 27
    Jul
CADL Candel Therapeutics
$6.20 /

+0.49 (+8.58%)

Over a month ago
Hot Stocks
Candel Therapeutics announces closing of initial public offering » 08:13
08/17/21
08/17
08:13
08/17/21
08:13
CADL

Candel Therapeutics

$7.29 /

-0.35 (-4.58%)

Candel Therapeutics…

Candel Therapeutics announced the closing of the issuance of an additional 887,994 shares of its common stock at a public offering price of $8.00 per share. The shares were issued pursuant to a partial exercise of the underwriters' option to purchase additional shares of common stock in connection with Candel's previously announced initial public offering of 9,000,000 shares of its common stock. The gross proceeds from the exercise of the option to purchase additional shares were approximately $7.1 million, bringing the aggregate gross proceeds to Candel from its initial public offering to approximately $79.1 million, before deducting underwriting discounts and commissions and other offering expenses.

ShowHide Related Items >><<
  • 27
    Jul
CADL Candel Therapeutics
$7.29 /

-0.35 (-4.58%)

On The Fly
Opening Day: Southern States, Eliem Therapeutics rise in market debut » 08:07
08/14/21
08/14
08:07
08/14/21
08:07
DATS

DatChat

$3.41 /

-0.44 (-11.43%)

, DRMA

Dermata Therapeutics

$5.19 /

-0.56 (-9.74%)

, SSBK

Southern States

$19.11 /

-0.79 (-3.97%)

, ELYM

Eliem Therapeutics

$14.78 /

-2.75 (-15.69%)

, CRBU

Caribou Biosciences

$24.18 /

+1.08 (+4.68%)

, OB

Outbrain

$19.71 /

-0.25 (-1.25%)

, SOPH

Sophia Genetics

$18.06 /

-0.08 (-0.44%)

, XPOF

Xponential Fitness

$11.69 /

-0.24 (-2.01%)

, CNM

Core & Main

$27.76 /

+0.34 (+1.24%)

, CTBK

CityBank

/

+

, GAMB

Gambling.com

$7.83 /

-0.01 (-0.13%)

, USCB

U.S. Century Bank

$11.86 /

+0.105 (+0.89%)

, RYAN

Ryan Specialty Group

$29.97 /

-0.01 (-0.03%)

, ABSI

Absci

$25.02 /

+1.225 (+5.15%)

, BASE

Couchbase

$34.56 /

+3.28 (+10.49%)

, ZENV

Zenvia

$11.27 /

-0.11 (-0.97%)

, ZVIA

Zevia

$12.78 /

-1.22 (-8.71%)

, INST

Instructure

$20.00 /

+0.52 (+2.67%)

, CADL

Candel Therapeutics

$7.52 /

-0.83 (-9.94%)

, PWSC

PowerSchool

$26.21 /

+1.06 (+4.21%)

, MLNK

MeridianLink

$25.27 /

+0.255 (+1.02%)

, SNPO

Snap One

$19.11 /

+0.36 (+1.92%)

, DUOL

Duolingo

$136.43 /

+2.43 (+1.81%)

, QNIU

Qiniu

/

+

, CMSL

Camposol

/

+

, SPRK

Spark Education

/

+

, SCAN

Perspectum Group

/

+

, AUTH

Authentic Brands Group

$8.01 /

+ (+0.00%)

, MS

Morgan Stanley

$103.95 /

-0.72 (-0.69%)

, GS

Goldman Sachs

$410.69 /

-4.39 (-1.06%)

, BCS

Barclays

$10.37 /

-0.02 (-0.19%)

, BAC

Bank of America

$41.64 /

-0.515 (-1.22%)

, SPG

Simon Property

$133.63 /

-0.17 (-0.13%)

, BLK

BlackRock

$916.64 /

-3.36 (-0.37%)

Eliem Therapeutics rose…

ShowHide Related Items >><<
SPG Simon Property
$133.63 /

-0.17 (-0.13%)

OB Outbrain
$19.71 /

-0.25 (-1.25%)

MS Morgan Stanley
$103.95 /

-0.72 (-0.69%)

GS Goldman Sachs
$410.69 /

-4.39 (-1.06%)

ELYM Eliem Therapeutics
$14.78 /

-2.75 (-15.69%)

DUOL Duolingo
$136.43 /

+2.43 (+1.81%)

CRBU Caribou Biosciences
$24.18 /

+1.08 (+4.68%)

BLK BlackRock
$916.64 /

-3.36 (-0.37%)

BCS Barclays
$10.37 /

-0.02 (-0.19%)

BAC Bank of America
$41.64 /

-0.515 (-1.22%)

AUTH Authentic Brands Group
$8.01 /

+ (+0.00%)

DATS DatChat
$3.41 /

-0.44 (-11.43%)

DRMA Dermata Therapeutics
$5.19 /

-0.56 (-9.74%)

SSBK Southern States
$19.11 /

-0.79 (-3.97%)

ELYM Eliem Therapeutics
$14.78 /

-2.75 (-15.69%)

CRBU Caribou Biosciences
$24.18 /

+1.08 (+4.68%)

OB Outbrain
$19.71 /

-0.25 (-1.25%)

SOPH Sophia Genetics
$18.06 /

-0.08 (-0.44%)

XPOF Xponential Fitness
$11.69 /

-0.24 (-2.01%)

CNM Core & Main
$27.76 /

+0.34 (+1.24%)

CTBK CityBank
/

+

GAMB Gambling.com
$7.83 /

-0.01 (-0.13%)

USCB U.S. Century Bank
$11.86 /

+0.105 (+0.89%)

RYAN Ryan Specialty Group
$29.97 /

-0.01 (-0.03%)

ABSI Absci
$25.02 /

+1.225 (+5.15%)

BASE Couchbase
$34.56 /

+3.28 (+10.49%)

ZENV Zenvia
$11.27 /

-0.11 (-0.97%)

ZVIA Zevia
$12.78 /

-1.22 (-8.71%)

INST Instructure
$20.00 /

+0.52 (+2.67%)

CADL Candel Therapeutics
$7.52 /

-0.83 (-9.94%)

PWSC PowerSchool
$26.21 /

+1.06 (+4.21%)

MLNK MeridianLink
$25.27 /

+0.255 (+1.02%)

SNPO Snap One
$19.11 /

+0.36 (+1.92%)

DUOL Duolingo
$136.43 /

+2.43 (+1.81%)

QNIU Qiniu
/

+

CMSL Camposol
/

+

SPRK Spark Education
/

+

SCAN Perspectum Group
/

+

AUTH Authentic Brands Group
$8.01 /

+ (+0.00%)

MS Morgan Stanley
$103.95 /

-0.72 (-0.69%)

08/13/21 Seaport Global
Morgan Stanley downgraded to Neutral at Seaport Global on valuation
08/13/21 Seaport Global
Morgan Stanley downgraded to Neutral from Buy at Seaport Global
07/19/21 Citi
Morgan Stanley price target raised to $97 from $88 at Citi
07/16/21 Argus
Morgan Stanley price target raised to $105 from $93 at Argus
GS Goldman Sachs
$410.69 /

-4.39 (-1.06%)

07/14/21 Oppenheimer
Goldman Sachs price target raised to $540 from $493 at Oppenheimer
07/14/21 Credit Suisse
Goldman Sachs price target raised to $425 from $420 at Credit Suisse
07/14/21 Mizuho
Affirm selloff on Apple competition fears overblown, says Mizuho
07/14/21 Piper Sandler
Goldman Sachs price target raised to $435 from $420 at Piper Sandler
BCS Barclays
$10.37 /

-0.02 (-0.19%)

08/02/21 RBC Capital
Barclays price target raised to 190 GBp from 180 GBp at RBC Capital
07/30/21 Morgan Stanley
Barclays price target raised to 205 GBp from 200 GBp at Morgan Stanley
07/29/21 UBS
Barclays price target raised to 220 GBp from 210 GBp at UBS
07/29/21 Deutsche Bank
Barclays price target raised to 240 GBp from 230 GBp at Deutsche Bank
BAC Bank of America
$41.64 /

-0.515 (-1.22%)

07/19/21 Odeon Capital
Bank of America downgraded to Hold from Buy at Odeon Capital
07/06/21 Keefe Bruyette
Bank of America assumed with a Market Perform at Keefe Bruyette
06/02/21 Truist
Bank of America initiated with a Buy at Truist
05/04/21
Fly Intel: Top five analyst downgrades
SPG Simon Property
$133.63 /

-0.17 (-0.13%)

08/13/21 Truist
Simon Property price target raised to $136 from $130 at Truist
08/13/21 Morgan Stanley
Simon Property price target raised to $161 from $150 at Morgan Stanley
08/04/21 BofA
Simon Property upgraded to Buy from Neutral at BofA
08/04/21 BofA
Simon Property upgraded to Buy from Neutral at BofA
BLK BlackRock
$916.64 /

-3.36 (-0.37%)

07/15/21 Credit Suisse
BlackRock price target lowered to $1,000 from $1,011 at Credit Suisse
07/15/21 Argus
BlackRock price target raised to $975 from $950 at Argus
07/15/21 Deutsche Bank
BlackRock price target lowered to $1,001 from $1,018 at Deutsche Bank
07/15/21 BMO Capital
BlackRock price target raised to $803 from $773 at BMO Capital
SPG Simon Property
$133.63 /

-0.17 (-0.13%)

MS Morgan Stanley
$103.95 /

-0.72 (-0.69%)

GS Goldman Sachs
$410.69 /

-4.39 (-1.06%)

DUOL Duolingo
$136.43 /

+2.43 (+1.81%)

BLK BlackRock
$916.64 /

-3.36 (-0.37%)

BCS Barclays
$10.37 /

-0.02 (-0.19%)

BAC Bank of America
$41.64 /

-0.515 (-1.22%)

  • 13
    Aug
  • 12
    Aug
  • 10
    Aug
  • 28
    Jul
  • 28
    Jul
  • 28
    Jul
  • 23
    Jul
  • 23
    Jul
  • 28
    Jul
  • 23
    Jul
  • 23
    Jul
  • 27
    Jul
  • 22
    Jul
  • 22
    Jul
  • 22
    Jul
  • 23
    Jul
  • 23
    Jul
  • 22
    Jul
  • 23
    Jul
  • 22
    Jul
  • 16
    Jul
  • 22
    Jul
  • 19
    Nov
MS Morgan Stanley
$103.95 /

-0.72 (-0.69%)

GS Goldman Sachs
$410.69 /

-4.39 (-1.06%)

DUOL Duolingo
$136.43 /

+2.43 (+1.81%)

BLK BlackRock
$916.64 /

-3.36 (-0.37%)

BCS Barclays
$10.37 /

-0.02 (-0.19%)

BAC Bank of America
$41.64 /

-0.515 (-1.22%)

AUTH Authentic Brands Group
$8.01 /

+ (+0.00%)

SPG Simon Property
$133.63 /

-0.17 (-0.13%)

QNIU Qiniu
/

+

GS Goldman Sachs
$410.69 /

-4.39 (-1.06%)

GAMB Gambling.com
$7.83 /

-0.01 (-0.13%)

DUOL Duolingo
$136.43 /

+2.43 (+1.81%)

CRBU Caribou Biosciences
$24.18 /

+1.08 (+4.68%)

CADL Candel Therapeutics
$7.52 /

-0.83 (-9.94%)

BLK BlackRock
$916.64 /

-3.36 (-0.37%)

AUTH Authentic Brands Group
$8.01 /

+ (+0.00%)

SPG Simon Property
$133.63 /

-0.17 (-0.13%)

MS Morgan Stanley
$103.95 /

-0.72 (-0.69%)

GS Goldman Sachs
$410.69 /

-4.39 (-1.06%)

DUOL Duolingo
$136.43 /

+2.43 (+1.81%)

CNM Core & Main
$27.76 /

+0.34 (+1.24%)

BAC Bank of America
$41.64 /

-0.515 (-1.22%)

On The Fly
Opening Day: Robinhood shares fall after IPO » 08:53
07/31/21
07/31
08:53
07/31/21
08:53
MXCT

MaxCyte

$16.89 /

-0.11 (-0.65%)

, RXST

RxSight

$16.42 /

-1.33 (-7.49%)

, TNYA

Tenaya Therapeutics

$15.75 /

-3.94 (-20.01%)

, RANI

Rani Therapeutics

$10.95 /

-0.37 (-3.27%)

, OMGA

Omega Therapeutics

$16.05 /

-4.43 (-21.63%)

, IMRX

Immuneering

$17.72 /

-1.94 (-9.87%)

, INAB

In8bio

$10.01 /

-0.13 (-1.28%)

, DOLE

Dole

$14.55 /

-0.65 (-4.28%)

, HOOD

Robinhood

$35.57 /

+0.75 (+2.15%)

, NUVL

Nuvalent

$18.42 /

-0.39 (-2.07%)

, ICVX

Icosavax

$25.00 /

-8.68 (-25.77%)

, RSKD

Riskified

$27.18 /

+0.99 (+3.78%)

, COOK

Traeger

$22.21 /

+0.2 (+0.91%)

, RLYB

Rallybio

$17.42 /

+3.02 (+20.97%)

, DUOL

Duolingo

$140.08 /

+3.13 (+2.29%)

, MLNK

MeridianLink

$23.90 /

-0.63 (-2.57%)

, PWSC

PowerSchool

$18.49 /

+0.02 (+0.11%)

, CADL

Candel Therapeutics

$7.63 /

+0.06 (+0.79%)

, SNTG

Sentage

$5.36 /

+0.55 (+11.43%)

, RNAZ

Transcode Therapeutics

$2.96 /

+0.035 (+1.20%)

, AGRI

AgriFORCE Growing Systems

$3.42 /

+0.32 (+10.32%)

, MITQ

Moving iMage

$3.89 /

-0.1 (-2.51%)

, IINN

Inspira Technologies

$3.88 /

-0.05 (-1.27%)

, UNCY

Unicycive Therapeutics

$2.76 /

-0.05 (-1.78%)

, SPRK

Spark Education

/

+

, QNIU

Qiniu

/

+

, CMSL

Camposol

/

+

, SCAN

Perspectum Group

/

+

, AUTH

Authentic Brands Group

$8.01 /

+ (+0.00%)

, MS

Morgan Stanley

$95.97 /

-0.295 (-0.31%)

, GS

Goldman Sachs

$375.04 /

-2.43 (-0.64%)

, BCS

Barclays

$9.78 /

-0.18 (-1.81%)

, BAC

Bank of America

$38.35 /

-0.335 (-0.87%)

, BLK

BlackRock

$867.23 /

-1.6 (-0.18%)

, SPG

Simon Property

$126.52 /

+0.63 (+0.50%)

Shares of Robinhood…

ShowHide Related Items >><<
SPG Simon Property
$126.52 /

+0.63 (+0.50%)

RLYB Rallybio
$17.42 /

+3.02 (+20.97%)

MS Morgan Stanley
$95.97 /

-0.295 (-0.31%)

MITQ Moving iMage
$3.89 /

-0.1 (-2.51%)

HOOD Robinhood
$35.57 /

+0.75 (+2.15%)

GS Goldman Sachs
$375.04 /

-2.43 (-0.64%)

BLK BlackRock
$867.23 /

-1.6 (-0.18%)

BCS Barclays
$9.78 /

-0.18 (-1.81%)

BAC Bank of America
$38.35 /

-0.335 (-0.87%)

AGRI AgriFORCE Growing Systems
$3.42 /

+0.32 (+10.32%)

MXCT MaxCyte
$16.89 /

-0.11 (-0.65%)

RXST RxSight
$16.42 /

-1.33 (-7.49%)

TNYA Tenaya Therapeutics
$15.75 /

-3.94 (-20.01%)

RANI Rani Therapeutics
$10.95 /

-0.37 (-3.27%)

OMGA Omega Therapeutics
$16.05 /

-4.43 (-21.63%)

IMRX Immuneering
$17.72 /

-1.94 (-9.87%)

INAB In8bio
$10.01 /

-0.13 (-1.28%)

DOLE Dole
$14.55 /

-0.65 (-4.28%)

HOOD Robinhood
$35.57 /

+0.75 (+2.15%)

07/29/21
Fly Intel: Top five analyst initiations
07/29/21 Atlantic Equities
Robinhood initiated with an Overweight at Atlantic Equities
NUVL Nuvalent
$18.42 /

-0.39 (-2.07%)

ICVX Icosavax
$25.00 /

-8.68 (-25.77%)

RSKD Riskified
$27.18 /

+0.99 (+3.78%)

COOK Traeger
$22.21 /

+0.2 (+0.91%)

RLYB Rallybio
$17.42 /

+3.02 (+20.97%)

DUOL Duolingo
$140.08 /

+3.13 (+2.29%)

MLNK MeridianLink
$23.90 /

-0.63 (-2.57%)

PWSC PowerSchool
$18.49 /

+0.02 (+0.11%)

CADL Candel Therapeutics
$7.63 /

+0.06 (+0.79%)

SNTG Sentage
$5.36 /

+0.55 (+11.43%)

RNAZ Transcode Therapeutics
$2.96 /

+0.035 (+1.20%)

AGRI AgriFORCE Growing Systems
$3.42 /

+0.32 (+10.32%)

MITQ Moving iMage
$3.89 /

-0.1 (-2.51%)

IINN Inspira Technologies
$3.88 /

-0.05 (-1.27%)

UNCY Unicycive Therapeutics
$2.76 /

-0.05 (-1.78%)

SPRK Spark Education
/

+

QNIU Qiniu
/

+

CMSL Camposol
/

+

SCAN Perspectum Group
/

+

AUTH Authentic Brands Group
$8.01 /

+ (+0.00%)

MS Morgan Stanley
$95.97 /

-0.295 (-0.31%)

07/19/21 Citi
Morgan Stanley price target raised to $97 from $88 at Citi
07/16/21 Argus
Morgan Stanley price target raised to $105 from $93 at Argus
07/16/21 BMO Capital
Morgan Stanley price target raised to $103 from $97 at BMO Capital
07/16/21 Piper Sandler
Morgan Stanley price target raised to $100 from $93 at Piper Sandler
GS Goldman Sachs
$375.04 /

-2.43 (-0.64%)

07/14/21 Oppenheimer
Goldman Sachs price target raised to $540 from $493 at Oppenheimer
07/14/21 Credit Suisse
Goldman Sachs price target raised to $425 from $420 at Credit Suisse
07/14/21 Mizuho
Affirm selloff on Apple competition fears overblown, says Mizuho
07/14/21 Piper Sandler
Goldman Sachs price target raised to $435 from $420 at Piper Sandler
BCS Barclays
$9.78 /

-0.18 (-1.81%)

07/30/21 Morgan Stanley
Barclays price target raised to 205 GBp from 200 GBp at Morgan Stanley
07/29/21 UBS
Barclays price target raised to 220 GBp from 210 GBp at UBS
07/29/21 Deutsche Bank
Barclays price target raised to 240 GBp from 230 GBp at Deutsche Bank
07/29/21 Societe Generale
Barclays price target raised to 180 GBp from 170 GBp at Societe Generale
BAC Bank of America
$38.35 /

-0.335 (-0.87%)

07/19/21 Odeon Capital
Bank of America downgraded to Hold from Buy at Odeon Capital
07/06/21 Keefe Bruyette
Bank of America assumed with a Market Perform at Keefe Bruyette
06/02/21 Truist
Bank of America initiated with a Buy at Truist
05/04/21
Fly Intel: Top five analyst downgrades
BLK BlackRock
$867.23 /

-1.6 (-0.18%)

07/15/21 Credit Suisse
BlackRock price target lowered to $1,000 from $1,011 at Credit Suisse
07/15/21 Argus
BlackRock price target raised to $975 from $950 at Argus
07/15/21 Deutsche Bank
BlackRock price target lowered to $1,001 from $1,018 at Deutsche Bank
07/15/21 BMO Capital
BlackRock price target raised to $803 from $773 at BMO Capital
SPG Simon Property
$126.52 /

+0.63 (+0.50%)

07/19/21 Stifel
Simon Property upgraded to Buy from Hold at Stifel
06/28/21 Scotiabank
Simon Property price target raised to $138 from $117 at Scotiabank
06/22/21 Truist
Simon Property price target raised to $130 from $102 at Truist
06/21/21 Stifel
Simon Property price target raised to $125 from $120 at Stifel
SPG Simon Property
$126.52 /

+0.63 (+0.50%)

MS Morgan Stanley
$95.97 /

-0.295 (-0.31%)

GS Goldman Sachs
$375.04 /

-2.43 (-0.64%)

BLK BlackRock
$867.23 /

-1.6 (-0.18%)

BCS Barclays
$9.78 /

-0.18 (-1.81%)

BAC Bank of America
$38.35 /

-0.335 (-0.87%)

  • 30
    Jul
  • 30
    Jul
  • 30
    Jul
  • 30
    Jul
  • 29
    Jul
  • 30
    Jul
  • 30
    Jul
  • 29
    Jul
  • 30
    Jul
  • 29
    Jul
  • 29
    Jul
  • 28
    Jul
  • 28
    Jul
  • 30
    Jul
  • 28
    Jul
  • 29
    Jul
  • 29
    Jul
  • 27
    Jul
  • 14
    Jul
  • 16
    Jul
  • 08
    Jul
  • 08
    Jul
  • 08
    Jul
  • 19
    Nov
  • 13
    Nov
MS Morgan Stanley
$95.97 /

-0.295 (-0.31%)

HOOD Robinhood
$35.57 /

+0.75 (+2.15%)

GS Goldman Sachs
$375.04 /

-2.43 (-0.64%)

DUOL Duolingo
$140.08 /

+3.13 (+2.29%)

DOLE Dole
$14.55 /

-0.65 (-4.28%)

BLK BlackRock
$867.23 /

-1.6 (-0.18%)

BCS Barclays
$9.78 /

-0.18 (-1.81%)

AUTH Authentic Brands Group
$8.01 /

+ (+0.00%)

SPRK Spark Education
/

+

SPG Simon Property
$126.52 /

+0.63 (+0.50%)

RXST RxSight
$16.42 /

-1.33 (-7.49%)

MS Morgan Stanley
$95.97 /

-0.295 (-0.31%)

HOOD Robinhood
$35.57 /

+0.75 (+2.15%)

GS Goldman Sachs
$375.04 /

-2.43 (-0.64%)

DUOL Duolingo
$140.08 /

+3.13 (+2.29%)

BLK BlackRock
$867.23 /

-1.6 (-0.18%)

BCS Barclays
$9.78 /

-0.18 (-1.81%)

BAC Bank of America
$38.35 /

-0.335 (-0.87%)

AUTH Authentic Brands Group
$8.01 /

+ (+0.00%)

SPG Simon Property
$126.52 /

+0.63 (+0.50%)

MS Morgan Stanley
$95.97 /

-0.295 (-0.31%)

GS Goldman Sachs
$375.04 /

-2.43 (-0.64%)

BAC Bank of America
$38.35 /

-0.335 (-0.87%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.